Reassessing the Potential of Myb-targeted Anti-cancer Therapy.

Transcription factor MYB is essential for the tumorigenesis of multiple cancers, especially leukemia, breast cancer, colon cancer, adenoid cystic carcinoma and brain cancer. Thus, MYB has been regarded as an attractive target for tumor therapy. However, pioneer studies of antisense oligodeoxynucleotides against MYB, which were launched three decades ago in leukemia therapy, were discontinued because of their unsatisfactory clinical outcomes. In recent years, the roles of MYB in tumor transformation have become increasingly clear. Moreover, the regulatory mechanisms of MYB, such as the vital effects of MYB co-regulators on MYB activity and of transcriptional elongation on MYB expression, have been unveiled. These observations have underpinned novel approaches in inhibiting MYB. This review discusses the structure, function and regulation of MYB, focusing on recent insights into MYB-associated oncogenesis and how MYB-targeted therapeutics can be explored. Additionally, the main MYB-targeted therapies, including novel genetic therapy, RNA interference, microRNAs and low-molecular-weight compounds, which are especially promising inhibitors that target MYB co-regulators and transcriptional elongation, are described, and their prospects are assessed.

Introduction

Cellular MYB (c-Myb) is the homologue of the viral MYB (v-Myb), which is expressed by the avian myeloblastosis virus (AMV) and avian leukemia virus E26, respectively. Aberrant expression of MYB was observed in myeloid and erythroid leukemias 1. Subsequently, it was identified as a transcription factor that was critical for cell proliferation and differentiation 2. MYB belongs to a family of transcription factors that comprises two highly homologous proteins, MYBL1/A-Myb and MYBL2/B-Myb that play critical roles in various mammalian tissues 3. This review will focus on MYB/c-Myb.

Apart from hematopoietic malignancies, aberrant expression of MYB is also associated with many malignant solid tumors 4. MYB is required at relatively high levels for tumor survival. Therefore, MYB seems to be a target for anti-cancer therapeutics with a strategy to differentiate the excessively proliferating tumor cells 5.

MYB-targeted therapeutics for the treatment of leukemia has been intensely investigated for three decades 6. However, the use of MYB-targeted therapeutics has been hindered by problems associated with the delivery, efficacy and toxicity of RNA interference approach 7. Moreover, transcription factors have been considered traditionally almost impossible for targeted therapy. Recent years, new emerging technological advances on targeting of transcription factors with small molecules and new insights regarding the MYB itself have led to exploring novel MYB-targeted therapeutics 7. It is hopeful that MYB-targeted therapy shed new light on anti-cancer therapeutics.

Structure and Function of Myb

The MYB gene (Figure 1A) is located on chromosome 6q23.3 and encodes a 75-kDa transcription factor with an N-terminal DNA-binding domain (DBD), a central transactivation domain (TAD) and a C-terminal negative regulatory domain (NRD) 8 (Figure 1B). The TAD is required for the activation of its target genes 5, 7. The v-Myb protein is truncated at both N- and C- termini. It induces leukemia by transforming immature hematopoietic cells 9. Truncations at either N- or C-termini of the MYB gene are sufficient to induce transformation 10.

Figure 1

Structure of MYB and its co-regulators. (A) The MYB proto-oncogene consists of 15 normal exons and many alternative spliced exons such as 8A, 9A, 9B, 10A, 13A and 14A. The 3' untranslated region is shown in gray. Transcription is initiated from multiple start sites and is regulated by the attenuator sequence (Atn) within intron 1.(B) The normal MYB protein contains the DNA-binding domain (DBD), transactivation domain (TAD) and negative regulatory domain (NRD). The post-translational modifications such as phosphorylation (P), acetylation (AC) and sumoylation (SUMO) as well as the EVES peptide sequence that is involved in intra- and intermolecular protein-protein interactions are also shown. The MYB co-activators are listed in green and the co-repressors are listed in red. Arrows indicate potential intramolecular interactions. (C) Schematic representation of MYB variants expressed in leukemia and solid tumors. Both AMV v-Myb and E26 proteins are truncated at both the N- and C-termini of c-MYB. The AMV v-Myb protein contains 6 amino acids derived from the retroviral Gag protein fused to amino acids 72-442 of MYB followed by 13 novel amino acids at the C-terminus (shaded gray). It also has 11 point mutations that cause amino acid changes (gray dots). The E26 protein is a Gag-MYB-Ets fusion protein with 272 amino acids of the retroviral Gag protein fused to MYB, which in turn is fused to 491 amino acids from Ets-1transcription factor at the C-terminus. Aberrant expression of MYB-9A in adult T-cell leukemia correlates with poor outcomes. C-terminal truncated protein has also been identified inTK-6, a chronic myeloid leukemia (CML) cell line. The fusion of MYB and NFIB genes (translocation 6; 9) generates a MYB-NFIB fusion protein in adenoid cystic carcinoma (ACC) that resembles truncated MYB protein. In brain tumors, MYB-QKI fusion gene generates similar MYB fusion protein lacking C-terminal domains.

Highly conserved DBD includes three tandem repeats (R1, R2, and R3), the first of which is deleted in the AMV and E26 oncoproteins 4 (Figure 1B and Figure 1C). R1 stabilizes the MYB-DNA complex. R2 and R3 form the core DNA binding domain 11. Apart from DNA binding, DBD is involved in protein-protein interactions and activation of the target genes, which was identified by studying the activation of the first known MYB-regulated gene, mim-1. Mim-1 was activated by MYB, AMV and E26 proteins by binding to its promoter in reporter gene assays. However, AMV failed to activate the endogenous mim-1 gene embedded in cellular chromatin; while MYB and E26 proteins activated the endogenous gene. The critical reason is that three amino acid changes only in DBD of AMV (Figure 1C) disrupt its interaction with C/EBPbeta protein 12.

The C-terminal NRD suppresses the transforming activity of MYB 13. NRD contains EVES motif, which mediates inter- and intra-molecular regulation of MYB 14 (Figure 1B). The N- and C- termini of the MYB protein interact with each other through EVES motif, resulting in transcriptional inactivation. Interestingly, a competing EVES motif is present in p100, which is a ubiquitously expressed transcriptional co-activator in diverse species. MYB adopts an open configuration by interacting with p100, which enables its interaction with additional co-activators 6. In case of v-Myb, the auto-regulation is absent because of the C-terminal truncation resulting in absence of the EVES motif (Figure 1C).

Interactions between Myb and its Co-regulators

As shown in Figure 1B, MYB transcription factor, interacts with various co-regulators including C/EBPbeta and p100 7, 13. Protein-protein interactions determine the specificity of MYB as well as its ability to induce proliferation or differentiation 9. For example, as mentioned above, MYB and C/EBPbeta interaction is necessary to activate MYB target genes 12, and the interaction between MYB and p100 regulates MYB activity 6.

CREB-binding protein (CBP) and p300 are also co-activators of MYB, which bind to the MYB TAD and acetylate MYB (Figure 1B), subsequently altering the protein-protein interactions and specificity of MYB 13. In mice harboring the MYB M303V mutation, the disruption of MYB and p300 interaction leads to increased number of hematopoietic stem cells and blocks the development of blood cells 15. This suggests that MYB and p300 interaction is critical for the normal proliferation and differentiation of hematopoietic stem and progenitor cells.

C-Ski, N-CoR, and mSin3A are 3 co-repressors that bind to the MYB DBD and form a complex with TIF1beta (Figure 1B). TIF1beta binds to the C-terminus and recruits the histone deacetylase complex to MYB, thereby negatively regulating MYB activity. Mutations or deletions in the NRD or DBD decrease the interaction of MYB with its co-repressors and increase its oncogenic transactivation 2. The c-Ski co-repressor protein competes with CBP for binding to MYB 9. These studies indicate that interaction with co-activators or co-repressors is critical for MYB-dependent transcription.

Moreover, NRD contains numerous sites for post-translational modifications like acetylation, phosphorylation, sumoylation and ubiquitinylation 13 (Figure 1B). For example, it contains the binding site of Pin1 (Figure 1B), an isomerase that binds to phosphorylated Ser/Thr-Pro motif and upregulates MYB activity 16. Wnt-1 also induces phosphorylation of MYB at multiple NRD sites, which is followed by ubiquitination and proteasome-dependent degradation of MYB 9. Therefore, co-regulators and post-translational modifications regulate the activity or stability of MYB. The oncogenic v-Myb protein lacks phosphorylation and ubiquitinylation sites resulting in resistance to Wnt-1 induced degradation. This partially explains the transformational capacity of v-Myb.

A substantial number of MYB target genes are involved in diverse cellular functions like proliferation, differentiation, cell cycle, apoptosis, cell signaling, angiogenesis and cell adhesion 2. These include cyclin genes (CCNA1, CCNE1, CCNB1), proto-oncogenes (MYC and KIT) and survival gene (BCL-2), which are also critical for tumorigenesis 9. Other MYB target genes linked to tumorigenesis include COX-2, BCL-XL, MIM1, CD4, CCNB1, HSPA5, HSP70 and GATA3 2.

Regulation of Myb Expression by MicroRNAs

The 3'untranslated region (3'UTR) of MYB contains binding sites for several miRNAs that regulate the turnover and translation of MYB mRNA 17. For example, miR-150 binds to the MYB 3'-UTR and down-regulates MYB expression in a stage-specific manner in B-cell development as well as differentiation of other hematopoietic lineages 18. Granulocytes from patients with primary myelofibrosis (PMF) demonstrate low miR-150 levels associated with MYB overexpression 19. Other tumor suppressor miRNAs associated with MYB include miRNA-193b-3p and miRNA-103a 20, 21.

Role of Myb in Normal Cells

MYB expression is high in hematopoietic progenitor cells and decreases during differentiation 2. Antisense knockdown of MYB expression in human bone marrow cells decreases the size of colonies and the number of the mononuclear cells 22. Homozygous MYB mutant mice die by embryonic day 15 due to hematopoietic failure 23. Studies with conditional MYB knockout mice show that precise expression of MYB is necessary for T- and B- cell development, myelopoiesis, erythropoiesis and HSC self-renewal 7. Therefore, MYB is essential for maintaining the proliferative state of hematopoietic progenitor cells as well as distinct differentiation steps in most hematopoietic cell lineages.

MYB expression has also been identified to be critical for the normal differentiation and progenitor cell homeostasis of colonic crypts and neurogenic region of the adult brain 2, 24, 25. Furthermore, recent conditional knockout studies showed evidence that MYB is globally expressed in many tissues and cells and is required for their normal development 4.

Role of Myb in Leukemias and Solid Tumors

Elevated MYB expression has been reported in many cases of leukemias, colon and breast cancers 7, 26-29. Recurrent translocations, duplications and C-terminal deletions have also been reported in leukemia, colon cancer, breast cancer, adenoid cystic carcinoma and brain cancer 2, 9, 30-34 (Figure 1C and Table 1).

Table 1

Human malignancies associated with MYB

Study	Tumor entity	Abnormality
Ferrari et al 1985	AML and ALL	MYB overexpression
Barletta et al 1987	Leukemia and lymphoma carrying 6q- deletions	MYB overexpression
Tomita et al 1998	TK-6 cell line (CML in T cell blast crisis)	MYB truncation
Clappier et al 2007	T-cell acute leukemia	Recurrent chromosomal translocation and genomic duplication of MYB locus
Murati et al 2009	Acute myelomonocytic leukemia	Genomic gain of the MYB locus
Quelen et al 2011	Acute basophilic leukemia	Recurrent translocation involving MYB
Nakano et al 2016	Adult T-cell Leukemia	MYB (unbalanced MYB-9A) overexpression
Alitalo et al 1984	Colon cancer	MYB overexpression; amplified MYB oncogene
Thompson et al 1997	Colon cancer	MYB overexpression; microsatellite deletions in MYB transcriptional attenuator region
Hugo et al 2006	Colon cancer	MYB overexpression; mutations in MYB intron 1 regulatory sequence
Guérin et al 1990	Breast cancer	MYB expression associated with oestrogen-receptor expression
Kauraniemi et al 2000	Hereditary breast cancer	MYB overexpression; amplified MYB oncogene
Persson et al 2009	Adenoid cystic carcinoma	Recurrent translocation involving MYB
Drier et al 2016	Adenoid cystic carcinoma	Recurrent translocation involving MYB
Zhang et al 2013	Brain tumor	Recurrent translocation involving MYB
Ramkissoon et al 2017	Brain tumor	Recurrent translocation involving MYB

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia

Moreover, high MYB expression has been proved to block differentiation and promote proliferation in most human leukemias and brain cancer 7, 35, and to be required for the maintenance of proliferation in primary human leukemia cells 36. Furthermore, recently, Liu et al demonstrated the tumorigenic potential of MYB in zebrafish model 37. In their study, transgenic zebrafish with hyperactive MYB (MYBhyper) exhibited abnormal granulocyte expansion resembling human myelodysplastic syndrome (MDS). And few MYBhyper adult fish developed acute myeloid or lymphoid- and leukemia-like disorders with age. Moreover, the MYB target drug, Flavopiridol, relieved MDS-like symptoms in both MYBhyper embryos and adult fish.

It has been suggested that tissues with essential roles for MYB in development and/or homeostasis like bone marrow, colon, brain and mammary gland are also susceptible to MYB-dependent oncogenesis 2. Additionally, alternative splicing of human MYB transcripts produces multiple forms of the MYB protein that have the same DBD, but different C-termini (Figure 1C). This results in differential MYB activities that correlate with cancer prognosis 38. For example, MYB9A expression correlates with poor survival for leukemia patients 35.

Co-operation between Myb and Other Oncogenes

MYB is an essential downstream effector for MLL-ENL and homeobox-mediated transformation in MLL-associated leukemia 39, 40. In a mouse model of human MLL-ENL leukemia, short-term siRNA suppression of MYB effectively inhibited leukemiagenesis by MLL-ENL 39. Moreover, in mouse model of MLL-AF9 related acute myeloid leukemia (AML), MYB knockdown decreased the number of leukemia stem cells (LSCs) 41.

MYB is also a pivotal regulator of oncogenic super-enhancers, which are large regulatory elements that drive the expression of critical oncogenes. In T-cell acute lymphoblastic leukemias, MYB recruits histone H3 lysine 27 (H3K27) acetylase-binding partners like CBP, RUNX1 and GATA-3, which act as a super-enhancer driving the expression of the TAL1 oncogene 42. In MLL-associated leukemogenesis, MYB was also identified to bind upstream of MLL through menin and contribute to MLL-mediated methylation of histone H3 at lysine 4 (H3K4) 43.

MYB is also involved in leukemogenesis triggered by other oncogenes like E2A-HLF, BCR-ABL, AML1-ETO and Setbp1 missense mutants 7, 40. These oncogenes aberrantly modulate the MYB-related transcriptional program resulting in leukemiogenesis. Therefore, MYB is indispensable for the initiation and/or maintenance of leukemia 7 and is an attractive target for leukemic therapy.

Elongation Control Regulates Myb Transcription

In most malignancies, MYB overexpression is due to increased transcriptional rate. MYB transcription is predominantly regulated by elongation control sequences within intron 1 that generate a RNA stem loop and a poly U tract, which stalls RNA polymerase II (RNA Pol II). RNA Pol II overcomes this transcription blockade by recruiting positive elongation transcription factor B (PTEFB) to the transcriptional attenuation region or due to mutations in the elongation control sequences of intron 1 (Figure 2). This results in increased transcription of MYB in tumors 2.

Figure 2

Model for the regulation of MYB transcriptional elongation. MYB transcriptional elongation is regulated by sequences within intron 1, which encode a RNA stem loop and a poly U tract of 19 uridines that stall RNA polymerase II (RNA Pol II). RNA Pol II overcomes transcription blockade through the attenuation region to express full-length MYB transcripts in normal cells. In colon cancer, the sequences encoding the stem loop or poly U tract are mutated, which disrupts transcriptional attenuation. In ER+ breast cancer, estrogen receptor α (ERα) and the PTEFB complex are recruited to the transcriptional attenuation region upon estrogen stimulation. Transcriptional block is relieved by the phosphorylation of the Ser-2 residue of RNA Pol II by the CDK9 subunit of PTEFB. In human leukemia cells, MYB transcriptional elongation is facilitated by the binding of the NFκB p50-p65 heterodimer to the stem loop, which mediates the recruitment of PTEFB and subsequent Ser-2 phosphorylation of RNA Pol II by CDK9.

In colon cancer, MYB expression is regulated by controlling transcriptional elongation by the attenuator sequences within intron 1, which are mutated in many instances 27 (Figure 2). The mutations facilitate transcriptional elongation and increase read-through, thereby increasing MYB expression in cancer cells 2.

In estrogen receptor positive (ER+) breast cancer, B lymphoma and erythroleukemia cells, the activity of PTEFB is essential within the transcription attenuation region of the MYB gene to resume transcriptional elongation 44-47. In ER+ breast cancer cells, ER recruits PTEFB when bound to estrogen 44 (Figure 2). The ER/PTEFB complex interacts with the MYB gene, phosphorylates RNA Pol II and relieves the attenuation of elongation. In leukemia cells, PTEFB is recruited when the NFκB heterodimer binds to the stem loop resulting in subsequent phosphorylation of RNA Pol II, which facilitates MYB transcription 45 (Figure 2). Therefore, suppressing PTEFB activity is a potential strategy to inhibit MYB expression in malignancies 48.

Myb as a Target for Anti-cancer Therapy

Several approaches have been attempted to inhibit aberrant MYB expression in cancer cells. These strategies include disrupting co-regulator interactions, promoting MYB transcription attenuation, targeting MYB upstream or downstream effectors, cancer vaccines, antisense oligodeoxynucleotides (short-hairpin RNA), overexpressing miRNAs that target MYB directly and low-molecular-weight compounds.

Antisense ODNs and Short Hairpin RNAs

Three decades ago, Gewirtz et al used antisense ODNs or shRNAs against MYB to effectively suppress growth and proliferation of primary patient derived leukemia cell lines in vitro 6. And leukemia cells were found to be more sensitive to MYB inhibition than normal hematopoietic cells 49. The MYB-specific antisense ODNs were also identified to be effective in a K562 leukemia model in SCID mice 50. However, MYB-specific antisense ODNs showed limited efficacy in the pilot study of chronic myelogenous leukemia patients 51. On the other hand, the antisense RNA and MYB ODNs have been proved to have the capacity to strongly inhibit proliferation of human colorectal cancer cells and transformed neuroectodermal cell lines in vitro. Moreover, the antisense MYB ODNs was shown to potentiate the anti-proliferative effects of conventional chemotherapeutic drugs such as taxol, 5-fluorouracil, vinblastine and doxorubicin 52, 53.

Over the last decade, many studies have attempted RNA interference (RNAi) to suppress MYB. In a mouse model of MLL-AF9 leukemia, the MYB specific shRNAs silenced MYB effectively and achieved complete remission and eradication of the aggressive leukemia without preventing normal myelopoiesis 41. Furthermore, in mouse model of pre-B-cell acute lymphoblastic leukemia, the MYB shRNA decreased proliferation of leukemia cells and increased their sensitivity to cytotoxic agents, thereby significantly delaying disease onset 54.

Many studies explored combining MYB antisense ODNs with other targeted therapies. For example, MYB antisense ODNs synergized with GD2-specific antibodies achieved long term survival in murine xenograft models of neuroblastoma 55. The liposomes were coated with the anti-GD2 antibodies (targeted liposomes) and MYB antisense ODNs. The GD2-targeted liposomes successfully delivered the ODNs to the target cells and enhanced their toxicity without affecting the normal cells. Additionally, the CpG motifs stimulated the immune cells. Therefore, MYB RNAi can effectively inhibit the proliferation of leukemia and other tumor cells and cooperate with other cytotoxic agents or targeted therapies. But, MYB RNAi still requires improvements in effective delivery, stability and toxicity for implementation in clinical applications 7.

Myb DNA Vaccine

Overexpression of MYB occurs in 80% of colorectal cancer (CRC) and is associated with aggressive disease and poor prognosis 56. Ramsay et al tested MYB DNA vaccine in a mouse model of colorectal cancer. The MYB DNA vaccine suppressed colorectal tumor growth by inducing the T cell-mediated immunity and increasing the infiltration of immune effector cells at the tumor site 56. Moreover, in the CRC mice model, the MYB DNA vaccine in combination with anti-PD-1 antibody or low dose cyclophosphamide effectively killed tumor cells 57. Pre-clinical and clinical studies are needed to explore the utility of MYB DNA vaccine in clinical applications.

Inhibition of Myb-coregulator Interactions

P300 has been investigated as a therapeutic target because it is an important co-activator of MYB 7. In the study on Booreana mice carry a mutant allele of MYB, which disrupts its interaction with p300, irradiated recipient mice transplanted with Booreana hematopoietic cells transduced with AML1-ETO9a or MLL-AF9 retroviruses did not develop leukemia 58. This indicates that disruption of the MYB and p300 interaction is a potential therapeutic strategy in malignancies relying on MYB 59.

The therapeutic efficacy of many small-molecule inhibitors of the MYB/p300 interaction have been investigated 60. Among these studies, Celastrol, a potent low molecular weight inhibitor, was shown to suppress the proliferative potential of AML cells without affecting normal hematopoietic progenitor cells. Moreover, Celastrol enhanced survival of the mice model of HoxA9/Meis1-driven AML 61.

Also, MYB is recruited to the MLL histone methyl transferase complex through its interaction with menin, and contributes to MLL-associated leukemogenesis 43. Therefore, the interaction of MYB with menin has been explored as an anti-cancer strategy. Grembecka et al demonstrated that several small-molecule inhibitors of the menin-MLL complex blocked transformation by MLL fusion proteins in bone marrow cells (BMC) and relieved the differentiation block in MLL-associated human leukemia cells 62.

Therapeutic Targeting of Myb Elongation

Since PTEFB activity correlates with elevated MYB expression, suppressing PTEFB activity is an attractive strategy to inhibit aberrant MYB expression 45, 48. Flavopiridol is an inhibitor of the Cdk9 subunit of PTEFB, which suppresses the expression of MYB and its target genes like BCL-2 and CCNB1 in ER + breast cancer cells. Moreover, Flavopiridol is at least 10 times more effective in eliminating ER+ breast cancer cell lines than ER-MYB- cells. The sensitivity of ER+ breast cancer cells could be reversed by ectopic MYB expression. This demonstrated that Flavopiridol is a potential therapeutic agent for ER+ breast cancers and other MYB-dependent cancers 63. In MYBhyper zebrafish studies, Flavopiridol relieved MDS-like symptoms in both MYBhyper embryos and adult fish 37. However, clinical trials of Flavopiridol in solid tumors were discontinued because of adverse events and low efficacy 64. Meanwhile, Flavopiridol shows clinical activity in several hematological malignancies such as chronic lymphocytic leukemia, but, the relevance between MYB suppression and clinical activity is ambiguous 65. Therefore, new, specific and more effective inhibitors of MYB elongation need to be developed.

Myb Specific MicroRNAs

Several MYB-targeting miRNAs demonstrate potential as anti-cancer therapeutics. Restoring miR-150 expression in EBV-positive Burkitt lymphoma cell lines decreased MYB levels, which reduced proliferation and induced differentiation in the lymphoma cells. Moreover, MYB knockdown showed similar characteristics to overexpressing miR-150 in the lymphoma cell lines 66. This showed therapeutic potential of miR-150 and other MYB targeting miRNAs in future anti-cancer therapy.

Other Approaches for Targeting Myb

Drugs with multiple targets are more effective than specific target drugs in the treatment of complex diseases such as cancer. The bromodomain and extra-terminal (BET) protein BRD4 has been identified to regulate the expression and activity of MYB in several modes. BRD4 regulates MYB expression through recruiting PTEFB, which promotes MYB elongation 67. It also regulates downstream effectors of MYB such as MYC, and MYB co-regulators including p300/CBP 68, 69. Hence, BRD4 inhibition is potentially an effective strategy for suppressing MYB. In fact, BRD4 inhibition is being tested as a therapy for acute leukemia and breast cancer with high-level MYB expression 70-72.

Additionally, since the positive feedback loop of MYB and Hoxa/Meis is critical for regulating leukemogenesis, Hox is a potential therapeutic target 43. Also, regulators of MYB degradation like the Wnt-1 signaling pathway have shown therapeutic potential.

Klempnauer et al reported several sesquiterpene lactones that suppressed MYB-dependent gene expression specifically 73. In their studies, mexicanin-I suppressed the proliferation of all MYB-expressing tumor cell lines and inhibited the colony growth of blasts from multiple AML patients; while tumor cell lines without MYB expression are less sensitive to mexicanin-I 74. Further investigations are in progress to evaluate the clinical efficacy of these novel low-molecular-weight MYB inhibitors.

More recently, the widely used mebendazole was identified to induce c-MYB degradation via the proteasome by interfering with the heat shock protein 70 (HSP70) chaperone system, which is sufficient to inhibit colony formation by AML cells, but not normal cord blood-derived cells. Moreover, mebendazole is effective at impairing AML progression in mouse experiments 75. It seems that mebendazole is also a safe and novel therapeutic approach for AML. Further research is ongoing.

Conclusions

The MYB transcription factor is a suitable target for tumor therapy because its aberrant expression is pivotal for the growth and progression of multiple solid tumors and leukemias. While MYB-targeted antisense ODNs have not been satisfactory in clinical studies, RNAi and miRNAs targeting MYB have shown great promise in preliminary studies. Moreover, better understanding of the regulation of the activity and expression of MYB and efficient inhibitor screens have opened up novel therapeutic avenues for low-molecular-weight inhibitors that target MYB co-regulators or its transcriptional elongation. Multiple inhibitors are effective in inhibiting tumors with elevated MYB expression in laboratory studies 59. Further investigations are in progress to evaluate their efficacy in pre-clinical and clinical studies. The focus of future studies include studying the efficacy of these inhibitors, their toxicity in animal models or preclinical studies, and screening promising inhibitors individually or in combination with conventional chemotherapeutics or other targeted drugs in clinical trials. Since MYB plays a central role in tumorigenesis, new and effective MYB inhibitors will contribute to improving the survival of patients with MYB-related tumors.